NF-κB dysregulation in SMZL represents a new biological basis for novel therapeutic strategies for SMZL patients. Proteasome inhibitors, that are already approved for other malignancies, or more specific anti-NF-κB compounds under development should be tested for their efficacy in clinical trials specifically dedicated to SMZL.
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.
ARCAINI, LUCA;
2012-01-01
Abstract
NF-κB dysregulation in SMZL represents a new biological basis for novel therapeutic strategies for SMZL patients. Proteasome inhibitors, that are already approved for other malignancies, or more specific anti-NF-κB compounds under development should be tested for their efficacy in clinical trials specifically dedicated to SMZL.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
